<DOC>
	<DOCNO>NCT00003298</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy , radiation therapy , surgery may kill tumor cell . E7296 conduct study neoadjuvant chemotherapy postoperative chemoradiation therapy patient diagnose high-risk gastric cancer use new neoadjuvant regimen : paclitaxel plus cisplatin . It hypothesize new neoadjuvant chemotherapy follow surgery chemoradiation therapy would well tolerate would high curative resection rate .</brief_summary>
	<brief_title>Chemotherapy , Surgery , Radiation Therapy Treating Patients With Gastric Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary objective : To evaluate tolerability toxicity neoadjuvant cisplatin plus paclitaxel postoperative chemoradiation therapy fluorouracil plus leucovorin calcium patient high-risk gastric cancer . Secondary objective : To assess pathologic response gastric tumor neoadjuvant cisplatin plus paclitaxel chemotherapy , preliminarily ass pattern failure disease free overall survival . OUTLINE : Patients receive 3 course preoperative neoadjuvant chemotherapy give day 1 every 21 day . Courses consist intravenous infusion cisplatin 3 hour intravenous infusion paclitaxel day 1 . Patients undergo surgery tumor removal day 63 , follow 4-6 week later one course daily intravenous bolus leucovorin calcium fluorouracil 5 day . Chemotherapy repeat 4-6 week later first 4 day week 1 last 3 day week 5 radiation therapy give 5 day week 5 week . Patients receive two course , 4 week apart , fluorouracil leucovorin calcium 5 day 4-6 week complete radiation treatment . Patients follow every month first 3 month , every 3 month next 21 month , every 6 month next year , annually thereafter . PROJECTED ACCRUAL : Approximately 30-42 patient accrue 18 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Formyltetrahydrofolates</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<criteria>Histologically confirm adenocarcinoma stomach gastroesophageal junction Localized cancer potentially curable surgery ( T2 , N12 , M0 T34 , N , M0 ) No metastatic cancer ovary Age : 18 Easter Cooperative Oncology Group ( ECOG ) performance status 02 White blood cell ( WBC ) count least 4,000 cells/mm3 Platelet count least 150,000/mm3 Bilirubin less 2 mg/dL Creatinine great 1.5 mg/dL Creatinine clearance great 50 mL/min Caloric intake must least 1500 kcal/day No prior history cancer within past 5 year except basal cell carcinoma skin situ carcinoma cervix No prior radiation therapy , except skin cancer Fertile patient must use adequate contraception Met criterion reregistration surgery T1N12M0 , T2N12M0 T34NanyM0 time initial reregistration . No evidence metastatic disease postoperative pathologic staging . ECOG performance status 0 , 1 , 2 reregistration Curative resection perform Reregistered 4 6 week date surgery WBC ≥ 4000 cells/mm³ , platelet ≥ 150,000/mm³ , creatinine ≤ 1.5 mg/dl creatinine clearance &gt; 50 ml/min ( measure calculate ) total serum bilirubin &lt; 2 mg/dl , within four week prior reregistration Prior chemotherapy Clinically significant auditory impairment Significant heart disease Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>